医学
沙利度胺
重症监护医学
不利影响
儿科研究
疾病
药物开发
悲剧(事件)
梅德林
儿科医学
药品
儿科
儿科医院
药品审批
临床药理学
风险评估
风险因素
作者
Gilbert J. Burckart,Susan M. Abdel‐Rahman,Gelareh A. Abulwerdi,Sherbet Samuels,Rebecca Racz,Mohamed Mohamoud,Nicholas P. Tatonetti
摘要
Pediatric drug development has achieved remarkable success in the last 20 years with over 1,000 products studied in pediatric patients. This success has been driven in part by an increased understanding of pediatric disease processes. The aspect that has been largely overlooked is the potential adverse effect of new drugs on pediatric developmental processes. The realization of this risk comes with the understanding that we could not predict another thalidomide worldwide tragedy even 70 years later.
科研通智能强力驱动
Strongly Powered by AbleSci AI